Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tempest TherapeuticsTPST -1.82%32 3-Year EBITDA Growth Rate is 45.20% as of Mar. 2026, which is 10% above its 10-year median of 41.00. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,137 Biotechnology companies, Tempest Therapeutics ranks better than 81.62% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 45.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 33.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tempest Therapeutics was 45.20% per year. The lowest was 14.30% per year. And the median was 41.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Tempest Therapeutics 3-Year EBITDA Growth Rate Related Terms
TPST vs HOWL, INTI, GTBP: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Tempest Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tempest Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Tempest Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 45.20% mean?
Tempest Therapeutics (TPST) has a 3-Year EBITDA Growth Rate of 45.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tempest Therapeutics and its competitors. This is 10% above median its historical median of 41.00. Over the past decade, Tempest Therapeutics' 3-Year EBITDA Growth Rate has ranged from 14.30 to 45.20. According to the industry distribution chart, Tempest Therapeutics ranks #209 out of 1137 companies in the Biotechnology industry, placing it in the top 18.4%.
Is Tempest Therapeutics' 3-Year EBITDA Growth Rate too high?
Tempest Therapeutics' current 3-Year EBITDA Growth Rate of 45.20% is 10% above median its 10-year median of 41.00. Over the past 10 years, this metric has ranged from a low of 14.30 to a high of 45.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Tempest Therapeutics' value of 45.20% is 203.4% above this industry median. Based on the distribution chart, Tempest Therapeutics ranks #209 out of 1137 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' 3-Year EBITDA Growth Rate compare to HOWL and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #209 out of 1137 companies for 3-Year EBITDA Growth Rate. This places Tempest Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Tempest Therapeutics' value of 45.20% is 203.4% above this benchmark. Historically, Tempest Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 14.30 to 45.20 over the past decade. While the company's 10-year median is 41.00 vs. the industry median of 14.90, Tempest Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tempest Therapeutics's current 3-Year EBITDA Growth Rate of 45.20% is 203.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tempest Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tempest Therapeutics's current 3-Year EBITDA Growth Rate is 45.20%, which is 10% above median its own 10-year median of 41.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current 3-Year EBITDA Growth Rate of 45.20%. The current 3-Year EBITDA Growth Rate is 45.20%, which is 10% above median its 10-year median of 41.00 and 203.4% above the Biotechnology industry median of 14.90. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current 3-Year EBITDA Growth Rate is 45.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score
Get the complete analysis for TPST
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPST has been successfully added to your 
